MedTrace Logo

Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori

NCT06412640 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2024-05-14

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy and safety of keverprazan with different doses of amoxicillin for Helicobacter Pylori.

Conditions

  • H. Pylori Infection

Interventions

DRUG

Keverprazan

Potassium-competitive acid blocker

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Zhenyu Zhang · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-12-01
Completion
2025-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06412640 on ClinicalTrials.gov